Skip to main content
TipRanks
Go Ultimate75% OFF

Karyopharm Therapeutics (25K0) Stock Forecast & Price Target

1 Followers
See the Price Targets and Ratings of:

25K0 Analyst Ratings

Moderate Buy
3Ratings
2Buy1Hold0Sell
Based on 3 analysts giving stock ratings to Karyopharm Therapeutics in the past 3 months

25K0 Stock 12 Month Forecast

€5.31▲(26458.85% Upside)
Based on 3 Wall Street analysts offering 12 month price targets for Karyopharm Therapeutics in the last 3 months. The average price target is EUR 5.31 with a high forecast of EUR 7.28 and a low forecast of EUR 3.35. The average price target represents a 26458.85% change from the last price of EUR 0.02.
Highest Price Target€7.28Average Price Target€5.31Lowest Price Target€3.35

Detailed List of Analyst Forecasts​

Analyst Type
Ranks
Analyst Rating
Upside/ Downside
Action
Analyst forecasts for DE:25K0
Price TargetArticle
Rodman & Renshaw―hold―Downgraded11/02/26
RBC Capital€7.28buy36281.99%UpsideReiterated10/27/26
Cantor Fitzgerald€3.35buy16635.72%UpsideReiterated09/01/26
H.C. Wainwright€11.82→€2.73hold13543.25%UpsideDowngraded07/31/26
Piper Sandler€14.55→€6.37buy31734.24%UpsideReiterated07/31/26
Robert W. Baird―hold―Downgraded07/31/26
Jefferies€12.73→€10.01buy49925.24%UpsideReiterated07/31/26
Leerink Partners Analyst forecast on DE:25K0Unknown AnalystNot RankedLeerink Partners€4.55→€6.37hold31734.24%UpsideReiterated05/15/26
Stocks with the Highest Top Analyst Consensus in the Healthcare Sector
PALIPalisade Bio
RZLTRezolute
MDWDMediwound
OVIDOvid Therapeutics
DFTXDefinium Therapeutics

Find stocks in the Healthcare sector that are highly recommended by Top Performing Analysts.

Best Analysts Covering Karyopharm Therapeutics

3 Months
Brian Abrahams
Brian AbrahamsRBC Capital
Success Rate10/33 ratings generated profit
30%
Average Return
-19.97%

Copying Brian Abrahams's trades and holding each position for 3 Months would result in 30.30% of your transactions generating a profit, with an average return of -19.97% per trade.

1 Year
Brian Abrahams
Brian AbrahamsRBC Capital
Success Rate5/33 ratings generated profit
15%
Average Return
-49.36%

Copying Brian Abrahams's trades and holding each position for 1 Year would result in 15.15% of your transactions generating a profit, with an average return of -49.36% per trade.

2 Years
Brian Abrahams
Brian AbrahamsRBC Capital
Success Rate0/33 ratings generated profit
0%
Average Return
-85.65%

Copying Brian Abrahams's trades and holding each position for 2 Years would result in 0.00% of your transactions generating a profit, with an average return of -85.65% per trade.

25K0 Analyst Recommendation Trends

05101520Dec 25Jan 26Feb 26Mar 26Apr 26May 26Jun 26Jul 26Aug 26Sep 26Oct 26Nov 26
Monthly rating counts for 25K0
RatingJul 26Aug 26Sep 26Oct 26Nov 26
Strong Buy55632
Buy32100
Hold32201
Sell00000
Strong Sell00000
total119933

In the current month, 25K0 has received 2 Buy Ratings, 1 Hold Ratings, and 0 Sell Ratings. 25K0 average Analyst price target in the past 3 months is 5.31.

25K0 Financial Forecast

€-1€9.9M€19.7M€29.6M€39.5MQ4 2025Q2 2026Q4 2026
Consensus€0.00

25K0 Sales Forecast

Next quarter’s sales forecast for 25K0 is EUR 0 with a range of ― to ―. The previous quarter’s sales results were EUR 29.98M. Its overall industry beat sales estimates 50.04% of the time in the past 12 months.

25K0 Stock Forecast FAQ

What is DE:25K0’s average 12-month price target, according to analysts?
Based on analyst ratings, Karyopharm Therapeutics’s 12-month average price target is €5.31.
What is DE:25K0’s upside potential, based on the analysts’ average price target?
Karyopharm Therapeutics has 26458.85% upside potential, based on the analysts’ average price target.
Can I see which stocks the top-ranking analysts are rating?
Yes, go to the Analysts’ Top Stocks tool to see stocks with a Strong Buy or Strong Sell analyst rating consensus, according to the top performers.
How can I follow the stock ratings of top Wall Street analysts?
Head over to our Expert Center to see a list of the top 100 Wall Street analysts and follow the analysts of your choice. Visit their profiles for more details about their stock ratings and see how they perform on a stock-by-stock basis.
Is Karyopharm Therapeutics a Buy, Sell or Hold?
Karyopharm Therapeutics has a consensus rating of Moderate Buy, which is based on 2 buy ratings, 1 hold ratings and 0 sell ratings.
What is Karyopharm Therapeutics’s share price target?
The average share price target for Karyopharm Therapeutics is €5.31. This is based on 3 Wall Street analysts’ 12-month price targets, issued in the past 3 months. The highest analyst share price target is €7.28, and the lowest forecast is €3.35. The average share price target represents a 26458.85% increase from the current price of €0.02.
What do analysts say about Karyopharm Therapeutics?
Karyopharm Therapeutics’s analyst rating consensus is a Moderate Buy. This is based on the ratings of 3 Wall Street analysts.
How can I buy shares of Karyopharm Therapeutics?
To buy shares of DE:25K0, you can open a brokerage account. See exclusive account opening deals on our Best Online Brokers page.